Brief: Sangamo Therapeutics Announces Research Evaluation And Option Agreement With Prevail

Sangamo Therapeutics

17/07/2023 13:22

July 17 (Reuters) - Sangamo Therapeutics Inc  SGMO.O :
    * SANGAMO THERAPEUTICS ANNOUNCES RESEARCH EVALUATION AND
OPTION
AGREEMENT WITH PREVAIL, A WHOLLY OWNED SUBSIDIARY OF LILLY, FOR
NOVEL ENGINEERED CAPSIDS
    * SANGAMO THERAPEUTICS INC - WILL PROVIDE CAPSIDS TO PREVAIL
FOR
EVALUATION IN EXCHANGE FOR AN UPFRONT PAYMENT
    * SANGAMO THERAPEUTICS INC - CO TO BE ELIGIBLE TO RECEIVE
EXERCISE
FEES AND DEVELOPMENTAL MILESTONES OF UP TO ABOUT $415 MILLION
    * SANGAMO THERAPEUTICS INC -  CO TO BE ELIGIBLE TO RECEIVE
COMMERCIAL MILESTONES OF UP TO ABOUT $775 MILLION
    * SANGAMO THERAPEUTICS INC - CO TO BE ELIGIBLE TO RECEIVE
TIERED
ROYALTIES BASED ON NET SALES OF PREVAIL PRODUCTS INCORPORATING
LICENSED CAPSIDS
    * SANGAMO THERAPEUTICS INC - PREVAIL WOULD LEAD ALL FURTHER
DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION OF PRODUCTS
INCORPORATING LICENSED CAPSIDS

Source text for Eikon:  ID:nBw1Vcp3da 
Further company coverage:  SGMO.O 

 ((Reuters.Briefs@thomsonreuters.com;))